This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Treating B-Cell Lymphomas: Novel Agents and the Evolving State of Practice

Treating B-Cell Lymphomas: Novel Agents and the Evolving State of Practice

Format

Slide Lecture Series

Time to Complete

1 hour

Released

April 8, 2019

Expires

April 8, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CE for Pharmacists

Accredited Provider

This activity is accredited by the Washington State Pharmacy Association and Horizon CME, and was planned and implemented in partnership between Horizon CME and RedMedEd.

Commercial Supporter

Support for this activity has been provided through educational grants from Celgene Corporation, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Program Description

Over the last several decades, advances in non-Hodgkin lymphoma (NHL) management have improved survival; however, relapse and the emergence of treatment-resistant NHL following standard therapy remain ongoing treatment challenges. With conventional therapy for B-cell NHL, response rates are suboptimal and many patients relapse, highlighting the need for novel treatments that address the risk of disease progression. Recently, several novel therapies—including small-molecule inhibitors of the B-cell receptor pathway and next-generation monoclonal antibody therapies—have emerged or advanced in clinical trials. These agents offer the potential to dramatically improve outcomes in some treatment-resistant patients.

This activity has been developed to help advanced-practice oncology professionals stay current on the newest targeted NHL therapies and the best strategies for their effective use, particularly in the management of patients with multidrug-resistant and relapsing NHL. Additionally, this activity reviews current best practices for detecting variations in the natural history of NHL over time with the goal of improving long-term outcomes.

Intended Audience

This activity has been designed to meet the educational needs of oncology nurse practitioners, physician assistants, pharmacists, nurse specialists, and other health care providers (HCPs) involved in the management of oncology patients.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate current recommendations and best practices for therapeutic management of B-cell lymphomas with respect to patient risk and the benefits and risks of available treatment regimens
  • Distinguish between the indicated uses, mechanisms of action, depth and duration of clinical responses, and safety of current and emerging targeted agents
  • Outline a treatment plan to achieve the deepest and most durable response while balancing the adverse effects and risk for toxicities in fit and unfit patients

Conflict Of Interest Disclosure Policy

All educational activities are developed and conducted in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME’s) Essential Areas and Policies. It is the mission of the accredited provider and its partners to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes. Toward the end, we welcome comments about how to better serve your needs.

Faculty

Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC, has disclosed the following relevant financial relationships:
Advisory Board: Cardinal Health, Mylan
Speakers Bureau: AbbVie, Genentech, Seattle Genetics

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Horizon CME designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM .

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education.

Designation Statement

This activity is approved for up to 1.00 credit hour by the Washington State Pharmacy Association.

Disclosure of Unlabled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information presented in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a health care provider regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the Washington State Pharmacy Association; Horizon CME; RedMedEd; Celgene Corporation; Pharmacyclics LLC, an AbbVie Company; or Janssen Biotech, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately and will not be stored in your myCME CME History.

In order to process CE credits, participants must have provided the correct NABP e-Profile ID number and their birth month and day (MMDD format) in the evaluation survey. The NABP eProfile ID number is a six to eight-digit number, and it is NOT your license number, NPI number, or store NABP#. If you need to verify your number or have not yet registered for one, please visit www.MyCPEMonitor.net.

The Washington State Pharmacy Association only has 60 days from the date of the activity to upload the CPE information to the CPE Monitor. It will be your responsibility to check the CPE Monitor before the 60 days to make sure the CE is uploaded in your profile. If there are any problems, you will need to contact WSPA 425-228-7171. This activity will be uploaded to the CPE Monitor on a monthly basis. Please check your CPE Monitor at this time to ensure the CE is uploaded in your profile.

For questions regarding CME credit, please contact info@horizoncme.com.

For technical questions related to this activity, please contact Horizon CME at (503) 659-5558 or info@horizoncme.com.

Privacy Policy

For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email/mailing address and payment information). This information is confidential and will only be used to contact you regarding your registration.

myCME privacy policy

Copyright

© 2019. This CME-certified program is held as copyrighted by the Washington State Pharmacy Association, Horizon CME, and RedMedEd. Through this notice, the Washington State Pharmacy Association, Horizon CME, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.
Add to Queue